Researchers Explore Innovative Approaches to HIV Cure and Brain Health

Advancements in immunotherapy and understanding the intersection of HIV, aging, and neurodegenerative diseases offer hope.

Mar. 30, 2026 at 12:36am by Ben Kaplan

Got story updates? Submit your updates here. ›

Researchers are making significant progress in the quest for an HIV cure, particularly through the use of immunotherapy approaches like broadly neutralizing antibodies (bNAbs) and immune-stimulating agents. Additionally, as people living with HIV (PLWH) live longer due to effective antiretroviral therapy (ART), researchers are increasingly focused on the intersection of HIV, aging, and long-term health, especially brain health and the potential impact of HIV on cognitive aging and neurodegenerative diseases.

Why it matters

The success of ART in transforming HIV from a death sentence into a manageable chronic condition has brought new complexities. While ART effectively suppresses the virus, it doesn't eliminate it, and as PLWH live longer, understanding the long-term health implications, particularly on brain health, is crucial. Achieving a cure for HIV and mitigating the risks associated with long-term HIV infection are essential to ending the AIDS epidemic.

The details

Researchers are exploring various strategies to achieve a cure for HIV, including boosting the immune system, gene therapy, and CAR T cells. The focus is shifting towards understanding how to leverage the body's own defenses to control or eradicate the virus. Elite controllers, individuals who naturally suppress HIV without ART, are providing valuable clues, exhibiting unique immunological and genetic characteristics. Several promising cases of potential HIV cure have been reported, including the 'Berlin Patient,' the 'London Patient,' and the 'Düsseldorf Patient,' often involving stem cell transplants and the CCR5 mutation.

  • A recent clinical study, led by Drs. Rachel Rutishauser and Steven Deeks at the University of California, San Francisco, and funded by amfAR, demonstrated long-term HIV control in some participants after stopping ART.
  • Ongoing clinical trials are testing various interventions, aiming to induce sustained ART-free HIV control and deepen our understanding of post-treatment control.

The players

Rachel Rutishauser

A researcher at the University of California, San Francisco who led a clinical study on long-term HIV control after stopping ART.

Steven Deeks

A researcher at the University of California, San Francisco who led a clinical study on long-term HIV control after stopping ART.

amfAR

An organization that funded the clinical study led by Drs. Rutishauser and Deeks on long-term HIV control after stopping ART.

Got photos? Submit your photos here. ›

What’s next

Ongoing clinical trials are testing various interventions, aiming to induce sustained ART-free HIV control and deepen our understanding of post-treatment control.

The takeaway

The future of HIV treatment is focused on more than just suppression. It's about achieving a cure, understanding the long-term health implications of living with HIV, and developing strategies to mitigate those risks. Continued research, innovative therapies, and a deeper understanding of the immune system are essential to ending the AIDS epidemic.